NCT02597634View on ClinicalTrials.gov

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

PHASE3CompletedINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Delayed Onset Muscle Soreness, DOMS

Interventions

DRUG

SST-0225

SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.

DRUG

Placebo

Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.

Trial Locations (3)

33024

Site #203, Hollywood

33143

Site #201, South Miami

65802

Site #202, Springfield

All Listed Sponsors

lead

Strategic Science & Technologies, LLC

INDUSTRY

NCT02597634 - Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS) | Biotech Hunter | Biotech Hunter